evocatal GmbH, a Düsseldorf, Germany-based biotech company that specializes in the development of biocatalysts and enzyme-based chemical processes, has closed € 2m in growth financing.
The investment was led by new investor Roland Oetker, with participation from existing venture partners High-Tech Gründerfonds (HTGF), Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner.
As also stated by Dr. Thorsten Eggert, founder and CEO of the company, this series B round will enable evocatal to realise the development of new products.
The company specialises in the development of new enzymes for use in the production of complex low-molecular weight compounds and fine chemicals for the pharmaceutical industry. evocatal has built up a portfolio of proprietary biocatalysts (evozymes®) and has commercialized a fluorescent protein for anaerobic applications in biotechnological research and development.
The company also develops new expression and secretion systems for enzyme production as well as innovative screening methods.
Founded in 2006, evocatal is based in the Life Science Center of Düsseldorf. In 2007, it had raised seed financing.